Category: BioTech

BioTech, Diversified Tech

WEX Posts Another Strong Quarter With Upside

WEX reported solid fourth-quarter results. Revenue grew 15% year-over-year and 8% from the prior quarter, to $182 million, and was above our estimate of $178 million and consensus of $177 million. Fourth-quarter adjusted EPS, excluding stock comp expense, were $1.17, above our $1.11 estimate. Including stock comp, adjusted EPS were $1.13, versus our $1.07 estimate, exceeding the top end of management guidance by $0.01. The … Continue reading WEX Posts Another Strong Quarter With Upside

Mark Doerr
BioTech, Diversified Tech

Improved Outlook for Solera Drives Another Increase to Guidance

Solera reported relatively in-line fiscal second-quarter results on Wednesday, February 5, and meaningfully increased its guidance for fiscal 2014. Adjusted EPS of $0.64 in the fiscal second quarter were $0.02 higher than our estimate and in line with the consensus. Revenue growth of 14% year-over-year in the quarter (about 6% organically) was in line with our estimate and a touch below the consensus. Management attributed … Continue reading Improved Outlook for Solera Drives Another Increase to Guidance

Jason Knox
BioTech, Tech IPO, Venture Capital

Manhattan Associates Post Solid Top Line Numbers

Manhattan Associates reported better than expected 3Q total revenue and EPS. License revenue was $1.7 million lighter than we expected, though the company made up the deficit on services. Investor sentiment was somewhat cautious heading into the print, resulting in the stock up marginally (1%- 3%) in after-hours trading. While MANH executed reasonably well, sluggish license revenue growth and valuation remain a stumbling block to … Continue reading Manhattan Associates Post Solid Top Line Numbers

Kristen Barton
BioTech, Software

Fusion-IO Fails to Deliver Expected Profits in Third Quarter

Following 2Q14 (Dec) results, many analysts are reiterating a Hold rating. On one hand, the company was able to exceed 2Q14 guidance. However, the company is still unprofitable and is guiding 3Q14 results to include an even greater loss. At this time, the company has no clear path to profitability other than a 35%-40% increase in revenue. Said differently, the company has yet to prove … Continue reading Fusion-IO Fails to Deliver Expected Profits in Third Quarter

Colin Pettis
BioTech, Software

GSE Systems Posts Respectable Q3 Performance in Tough Environment

Last night, GVP reported a good quarter, delivering contract revenue upside, in line GAAP EPS and relatively stable backlog in its 3Q13 earnings report. Despite posting a respectable performance, the company is still feeling the impact from stalled nuclear and non-nuclear simulator projects in the US, and from cancelled and delayed nuclear projects in Japan and Germany. We’re reiterating our Speculative Hold rating because we … Continue reading GSE Systems Posts Respectable Q3 Performance in Tough Environment

Adam Keintzel
Biotech Stock Finance Bio Tech
BioTech, Finance

Biotech Stock in News: The Medicines Co.’s Angiomax Gets Favorable Court Ruling

The Medicines Co (MDCO) announced that the U.S. District Court for the Northern District of Illinois has ruled in its favor in a patent infringement lawsuit against Mylan, Inc (MYL). Mylan was looking to get its generic version of The Medicines Co.’s Angiomax (European trade name: Angiox) approved in the U.S. The Medicines Co. stated that the Court declared its patent claims 1-3, 7-10 and … Continue reading Biotech Stock in News: The Medicines Co.’s Angiomax Gets Favorable Court Ruling

Richard Atkins